Pfizer Can't Escape Narrowed Off-Label Marketing FCA Suit

By Dani Kass (March 2, 2016, 6:01 PM EST) -- A Pennsylvania federal judge on Monday trimmed a False Claims Act suit against Pfizer Inc., but left room for the whistleblowers to refile and pursue other claims alleging illegal off-label marketing and kickback practices relating to the drugmaker's anti-fungal medication Vfend.

U.S. District Judge R. Barclay Surrick said part of the suit was barred by the FCA's first-to-file rule, which bans whistleblower suits over allegations that have already been brought to light, but gave leave to refile because the earlier suit was dismissed. The judge then shot down arguments from Pfizer that the FCA allegations more properly fit under the Food,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!